Business Wire

AL-JANADRIA-FESTIVAL

Share
The World's Largest Heritage and Culture Festival to Begin With the Slogan Janadria 33 Faithfulness and Loyalty

With the support and under the patronage of the Custodian of the Two Holy Mosques King Salman bin Abdulaziz, the 33rd Edition of the National Festival of Heritage and Culture will be held in Janadria for 21 days from Thursday 20th December 2018 to Wednesday 9th January 2019. Organized by the Saudi Ministry of National Guard, the festival is part of the efforts to intensify attention to Saudi heritage, expose it regionally and globally and to promote dialogue among cultures and civilizations on the level of people and nations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005472/en/

Janadria is the largest Saudi cultural festival that simulates the history, present and future of Saudi Arabia and the largest event of its kind in the region. Since 1985, it has witnessed extensive Saudi participation, a growing Arab and Gulf presence and an unprecedented public presence. The festival annually attracts millions of lovers of cultural heritage and originality and includes the launch of several distinctive cultural initiatives.

This year the festival is characterized by a wide and rich participation from the United Arab Emirates, the Sultanate of Oman, the Kingdom of Bahrain, and the guest of honor of the festival is Indonesia reflecting the weight of this historic, civilized and cultural country.

With a high-level official presence from the GCC and Arab countries, this year the festival’s theme is “Wafaa wa Walaa” – Faithfulness and Loyalty. The festival will present to the public a literary and artistic distinctive work, the opera performance “Tilal Ya Yaat” performed by Mohammed Abdo and Rashid Al Majid, with the words of the poet Fahd Aft and composed by the musician Dr. Talal and with the participation of the artist Mazal Farhan for the first time.

In addition there will be the launch of the camel race heritage, a race which is the first nucleus of the Janadria Festival known more than 40 years ago which then transformed into an annual cultural and heritage festival. The festival is also unique with “Al Arda Art” which represents one of the most important events and expresses the unity of the homeland and embodies the pride of the nation, its strength and cohesion.

The new edition is the largest in the history of the Festival, as it will be attended by more than 50 Saudi government institutions and sectors. The Festival will review the stands of the Saudi regions including folk shows, handicrafts, heritage collections, local food, seminars and cultural activities. The programme of folk literature at the Janadria Festival will have a wide participation of a number of famous Saudi, Emirati and Kuwaiti poets.

The festival seeks annually to provide all the amenities and needs for visitors to enjoy all its various activities and for their time spent at the event.

*Source: AETOSWire

Contact:

Pyramedia Reham Barakat Reham.barakat@pyramedia.biz

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye